الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 172 |  |  |
| | | from | 172 | | |
Abstract
DN is the leading cause of chronic kidney disease and end-stage renal disease in developing countries. Early detection and risk reduction measures can prevent DN. In Egypt, the prevalence of DN as a cause of end-stage renal disease increased from 8.9% of patients in 1996 to 14.5% in 2002.
This work was planned to investigate the possible application of CTS-SeNPs as a therapeutic agent in diabetic nephropathy in rats. Fifty male adult Wistar rats aged 8weeks and weighing 200-220gm, were used in the experimental investigation of this study. The animals were obtained from the Central Animal House of Faculty of Veterinary Medicine, Zagazig University.
After the acclimatization of animals for 2 weeks; fifty rats were assigned into five equal groups:
group 1: Control group (distilled water).
group 2: STZ-induced diabetic rats.
group 3: STZ-induced diabetic rats administered with Metformin (70 mg/kg/d).
group 4: STZ-induced diabetic rats administered with CTS-SeNPs at a dose (2 mg Se/kg/d).
group 5: STZ-induced diabetic rats administered with Metformin (70 mg/kg/d) and CTS-SeNPs at a dose (2 mg Se/kg/d).
At the end of experimental period (8 weeks) blood samples were collected from orbital venous plexus, centrifuged at 3000 r.p.m for 15 minutes, the resulting supernatant were collected and used for estimation of biochemical parameters.